Recent evaluations confirm that GLP-1 receptor agonists, including tirzepatide, can be confidently advanced due to their consistent safety and efficacy across diverse populations. They demonstrate significant reductions in body weight, cardiovascular risks, and all-cause mortality while also exhibiting renal protective effects. Participant feedback on the EBAQ has been overwhelmingly positive, indicating solid understanding of treatment protocols, supporting the program's advancement and real-world monitoring efforts.
Title not available for this citation.
“In expanded populations, comparing semaglutide versus sitagliptin for the composite outcome of myocardial infarction or stroke yielded a hazard ratio of 0.82 (95% confidence interval (CI) 0.74 to 0.91).”
Title not available for this citation.
“Comparing tirzepatide versus dulaglutide for the composite outcome including mortality yielded a hazard ratio of 0.87 (95% CI 0.75 to 1.01).”
Title not available for this citation.
“GLP-1RAs significantly reduced the risk of the primary composite outcome (RR 0.88, 95 % CI 0.84-0.91, P < 0.001).”
Title not available for this citation.
“GLP-1RAs and tirzepatide also significantly reduced the risk of death from any cause (RR 0.88, 95 % CI 0.84-0.92, P < 0.001).”
Title not available for this citation.
“GLP-1RAs and tirzepatide also significantly reduced the risk of death from cardiovascular causes (RR 0.88, 95 % CI 0.83-0.93, P < 0.001).”
Title not available for this citation.
“GLP-1RAs showed favorable overall safety profile, with a lower incidence of serious adverse events (RR 0.93, 95 % CI 0.89-0.99, P = 0.01).”
Title not available for this citation.
“Chronic kidney disease poses a major global health burden and is one of the most common complications of type 2 diabetes.”
Title not available for this citation.
“Drug trials have demonstrated that treatments, including sodium-glucose cotransporter-2 inhibitors, a glucagon-like peptide-1 receptor agonist, and a nonsteroidal mineralocorticoid receptor antagonist, mitigate chronic kidney disease progression.”
Title not available for this citation.
“The REMODEL trial is designed to explore the mechanisms of action of semaglutide with a novel multiparametric approach.”
Title not available for this citation.
“Better understanding of these mechanisms will help explain semaglutide's beneficial effects on kidney disease outcomes, reported in the FLOW trial.”
Title not available for this citation.
“Semaglutide and colorectal tumors: methodological pitfalls and translational gaps - Letter to the Editor.”
Title not available for this citation.
“The 21-item EBAQ is a new PRO measure with three domains to evaluate eight appetite and eating behavior concepts relevant to obesity...”